Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Raymond P. Abratt, Johann Raats, Fiona H Blackhall, Johan Vansteenkiste, Filippo de Marinis, Peter Langmuir, Jessica Read, Richard De Boer, Jürgen Wolf, Tsveta Milenkova, Chih-Hsin Yang, Valorie F. Chan, Maya Gottfried, Oscar Arrieta
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(8)
Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. This randomized, placebo-controlled phase III study assessed the efficacy of vandetanib plus pemetrexed a
Autor:
Maria Csollak, Filippo de Marinis, Giorgio V. Scagliotti, José Rodrigues Pereira, Beatrix Bálint, Martin Reck, Sandra DiMatteo, Francesco Grossi, Alan Keller, Silvia Novello, Nasser H. Hanna, I. Albert, Maciej Krzakowski, Joachim von Pawel, Osvaldo Rudy Aren, Frank Cihon, Carlos H. Barrios, Michael Thomas, Lisa Cupit, Jose Elias Abrao Miziara
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(11)
Purpose This phase III, multicenter, randomized, placebo-controlled trial assessed the efficacy and safety of sorafenib, an oral multikinase inhibitor, in combination with carboplatin and paclitaxel in chemotherapy-naïve patients with unresectable s
Autor:
Lawrence H. Einhorn, Frances A. Shepherd, Shaharyar, Klara Szondy, Miklos Pless, Paolo Paoletti, Thomas Müller, Radj Gervais, Joachim von Pawel, Christian Manegold, Paul A. Bunn, Ulrich Gatzemeier, Frank V. Fossella, Sofia Paul, Filippo de Marinis, Christopher Desch, José Rodrigues Pereira, Hong-Liang Lim, Nasser H. Hanna, Thomas Chang Yao Tsao
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 22(9)
PURPOSE To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy. PATIENTS AND METHODS Eligible patients had a performance status 0 to 2, pre